Bromazolam
Studies and references cited across this article, graded by evidence strength.
Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.
Data points an editor reviewed and accepted for publication.
Value Provenance
Dosing
oraltrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 0.25 mg | 0.25 mg | low |
| Low | 0.5–1 mg | 0.5–1 mg | low |
| Common | 1–2 mg | 1–2 mg | low |
| Strong | 2–4 mg | 2–4 mg | low |
| Heavy | 4+ mg | 4+ mg | low |
| Editorial | All dose values from community-reported data (TripSit) cited in WHO ECDD 45th and 46th meeting reports. Light 0.5–1 mg, common 1–2 mg, strong 2–4+ mg from these sources. Threshold 0.25 mg extrapolated from community 'light' floor — no published data. No controlled human dose-response study exists. No analytical confirmation of substance identity in community reports. Dose sensitivity flag: this is an emerging substance with no established therapeutic dose range. | ||
ReasoningReasoningAll dose values from community-reported data (TripSit) cited in WHO ECDD 45th and 46th meeting reports. Light 0.5–1 mg, common 1–2 mg, strong 2–4+ mg from these sources. Threshold 0.25 mg extrapolated from community 'light' floor — no published data. No controlled human dose-response study exists. No analytical confirmation of substance identity in community reports. Dose sensitivity flag: this is an emerging substance with no established therapeutic dose range. Evidence basis: community_consensus_small | |||
Duration
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 15–45 minutes | 15–45 minutes | low |
| Editorial | Community-reported onset 15–45 minutes from TripSit data cited in WHO ECDD 45th and 46th meeting reports. Anecdotal, no controlled PK data. | ||
ReasoningReasoningCommunity-reported onset 15–45 minutes from TripSit data cited in WHO ECDD 45th and 46th meeting reports. Anecdotal, no controlled PK data. Evidence basis: community_consensus_small | |||
| Come uptrace | 15–30 minutes | 15–30 minutes | low |
| Editorial | No published come_up data. Estimated at 15–30 minutes based on benzodiazepine class pharmacology (alprazolam Tmax ~1–2 hours) and reported total duration of 5–8 hours. | ||
ReasoningReasoningNo published come_up data. Estimated at 15–30 minutes based on benzodiazepine class pharmacology (alprazolam Tmax ~1–2 hours) and reported total duration of 5–8 hours. Evidence basis: structural_analogy | |||
| Peaktrace | 1–3 hours | 1–3 hours | low |
| Editorial | No published peak duration data. Estimated at 1–3 hours based on benzodiazepine class pharmacology and community-reported total duration of 5–8 hours. Alprazolam peak is ~1–2 hours. | ||
ReasoningReasoningNo published peak duration data. Estimated at 1–3 hours based on benzodiazepine class pharmacology and community-reported total duration of 5–8 hours. Alprazolam peak is ~1–2 hours. Evidence basis: structural_analogy | |||
| Offsettrace | 1–3 hours | 1–3 hours | low |
| Editorial | No published offset data. Estimated at 1–3 hours from benzodiazepine class inference and the constraint of 5–8 hour total duration minus onset, come_up, and peak phases. | ||
ReasoningReasoningNo published offset data. Estimated at 1–3 hours from benzodiazepine class inference and the constraint of 5–8 hour total duration minus onset, come_up, and peak phases. Evidence basis: structural_analogy | |||
| Totaltrace | 5–8 hours | 5–8 hours | low |
| Editorial | Community-reported total duration of 5–8 hours from TripSit data cited in WHO ECDD 45th and 46th meeting reports. Anecdotal, no controlled studies. | ||
ReasoningReasoningCommunity-reported total duration of 5–8 hours from TripSit data cited in WHO ECDD 45th and 46th meeting reports. Anecdotal, no controlled studies. Evidence basis: community_consensus_small | |||
| After effectstrace | 1–12 hours | 1–12 hours | low |
| Editorial | Community-reported after-effects of 1–12 hours from TripSit data cited in WHO ECDD 45th and 46th meeting reports. Wide range reflects inter-individual CYP variability and polydrug context. | ||
ReasoningReasoningCommunity-reported after-effects of 1–12 hours from TripSit data cited in WHO ECDD 45th and 46th meeting reports. Wide range reflects inter-individual CYP variability and polydrug context. Evidence basis: community_consensus_small | |||
Safety
Toxicity Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Acute | moderate | moderate | low |
| Chronic | moderate | moderate | low |
| Organs Affected | CNS, pulmonary, cardiovascular | CNS, pulmonary, cardiovascular | low |
| Editorial | No preclinical toxicity data exist. Acute 'moderate' based on case series documenting loss of consciousness and one cluster with seizures/hyperthermia/myocardial injury (Ehlers et al. 2024 MMWR), plus respiratory depression risk in polydrug contexts. Chronic 'moderate' based on documented dependence with life-threatening withdrawal seizures (Butler et al. 2025, McDermott et al. 2022). Cardiovascular organ entry from single Chicago cluster — may not be reproducible. | ||
ReasoningReasoningNo preclinical toxicity data exist. Acute 'moderate' based on case series documenting loss of consciousness and one cluster with seizures/hyperthermia/myocardial injury (Ehlers et al. 2024 MMWR), plus respiratory depression risk in polydrug contexts. Chronic 'moderate' based on documented dependence with life-threatening withdrawal seizures (Butler et al. 2025, McDermott et al. 2022). Cardiovascular organ entry from single Chicago cluster — may not be reproducible. Evidence basis: published_case_series | |||
Dependence Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Physical | high | high | medium |
| Psychological | high | high | medium |
| Compulsive Redosing | moderate | moderate | medium |
| Dose Escalation | moderate | moderate | medium |
| Editorial | Physical and psychological dependence rated 'high' based on benzodiazepine class inference supported by published case reports documenting clinically significant dependence (McDermott 2022, Butler 2025) and community reports of difficulty withdrawing (WHO ECDD 45th/46th). Compulsive redosing 'moderate' reflects community-reported delusions of sobriety facilitating unintended redosing. No formal dependence liability studies exist for bromazolam specifically. | ||
ReasoningReasoningPhysical and psychological dependence rated 'high' based on benzodiazepine class inference supported by published case reports documenting clinically significant dependence (McDermott 2022, Butler 2025) and community reports of difficulty withdrawing (WHO ECDD 45th/46th). Compulsive redosing 'moderate' reflects community-reported delusions of sobriety facilitating unintended redosing. No formal dependence liability studies exist for bromazolam specifically. Evidence basis: published_case_series | |||
Withdrawal Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Severity | life_threatening | life_threatening | medium |
| Symptoms | rebound anxiety, insomnia, seizures, psychosis, tremor, agitation, hallucinations | rebound anxiety, insomnia, seizures, psychosis, tremor, agitation, hallucinations | medium |
| Fatal | Yes | Yes | medium |
| Medical Supervision | Required | Required | medium |
| Editorial | Withdrawal seizures documented in Butler et al. 2025 (polydrug context including bromazolam). Withdrawal psychosis reported in community data cited by WHO ECDD. Onset, peak, and total duration are class-level estimates from benzodiazepine withdrawal literature — no bromazolam-specific withdrawal timeline characterized. No validated diazepam equivalency exists, complicating clinical taper management. | ||
ReasoningReasoningWithdrawal seizures documented in Butler et al. 2025 (polydrug context including bromazolam). Withdrawal psychosis reported in community data cited by WHO ECDD. Onset, peak, and total duration are class-level estimates from benzodiazepine withdrawal literature — no bromazolam-specific withdrawal timeline characterized. No validated diazepam equivalency exists, complicating clinical taper management. Evidence basis: published_case_series | |||
Tolerance Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Buildup | moderate | moderate | low |
| Half-life | 7 days | 7 days | low |
| Full Reset | 21 days | 21 days | low |
| Cross-tolerances | benzodiazepines, alcohol, barbiturates, zopiclone, zolpidem, zaleplon | benzodiazepines, alcohol, barbiturates, zopiclone, zolpidem, zaleplon | low |
| Editorial | Tolerance rated 'moderate' by benzodiazepine class inference (Navarrete et al. 2026 review). Half-life ~7 days and full reset ~21 days (2-4 weeks) estimated from benzodiazepine class literature using alprazolam as nearest structural analog. Cross-tolerances with all GABA-A PAMs inferred from shared mechanism. No bromazolam-specific data. | ||
ReasoningReasoningTolerance rated 'moderate' by benzodiazepine class inference (Navarrete et al. 2026 review). Half-life ~7 days and full reset ~21 days (2-4 weeks) estimated from benzodiazepine class literature using alprazolam as nearest structural analog. Cross-tolerances with all GABA-A PAMs inferred from shared mechanism. No bromazolam-specific data. Evidence basis: structural_analogy | |||
Effects & Profile
Contraindications
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| hepatic Hepatic impairmenttrace | relative | relative | medium |
| Editorial | Based on characterized CYP3A4-dominant metabolic pathway (Wagmann et al. 2021). Alprazolam, the chloro analog, carries the same contraindication. | ||
ReasoningReasoningBased on characterized CYP3A4-dominant metabolic pathway (Wagmann et al. 2021). Alprazolam, the chloro analog, carries the same contraindication. | |||
| respiratory Concurrent opioid usetrace | absolute | absolute | high |
| Editorial | Direct evidence from multiple postmortem case series (WHO ECDD 45th/46th reports, Hughes et al. 2026). Not class extrapolation — substance-specific epidemiological data. | ||
ReasoningReasoningDirect evidence from multiple postmortem case series (WHO ECDD 45th/46th reports, Hughes et al. 2026). Not class extrapolation — substance-specific epidemiological data. | |||
| respiratory Severe respiratory insufficiencytrace | absolute | absolute | medium |
| Editorial | Benzodiazepine class contraindication supported by bromazolam's confirmed full agonist activity (Emax 88%) at GABA-A receptors. No bromazolam-specific respiratory studies. | ||
ReasoningReasoningBenzodiazepine class contraindication supported by bromazolam's confirmed full agonist activity (Emax 88%) at GABA-A receptors. No bromazolam-specific respiratory studies. | |||
| immunological Known benzodiazepine hypersensitivitytrace | absolute | absolute | medium |
| Editorial | Standard benzodiazepine class contraindication. No bromazolam-specific allergy data exist. | ||
ReasoningReasoningStandard benzodiazepine class contraindication. No bromazolam-specific allergy data exist. | |||
| psychiatric History of substance use disordertrace | relative | relative | high |
| Editorial | Direct animal evidence of abuse potential (Paronis 2022 via WHO ECDD 46th) plus published case reports of dependence (McDermott 2022, Butler 2025). | ||
ReasoningReasoningDirect animal evidence of abuse potential (Paronis 2022 via WHO ECDD 46th) plus published case reports of dependence (McDermott 2022, Butler 2025). | |||
| metabolic Concurrent CYP3A4 inhibitorstrace | relative | relative | medium |
| Editorial | CYP3A4 identified as dominant Phase I enzyme by Wagmann et al. 2021. Interaction prediction is structural analogy from alprazolam; no bromazolam-specific interaction studies. | ||
ReasoningReasoningCYP3A4 identified as dominant Phase I enzyme by Wagmann et al. 2021. Interaction prediction is structural analogy from alprazolam; no bromazolam-specific interaction studies. | |||
| pregnancy breastfeeding Pregnancytrace | relative | relative | low |
| Editorial | Class-level extrapolation from benzodiazepine teratogenicity literature. No bromazolam-specific animal or human reproductive data. | ||
ReasoningReasoningClass-level extrapolation from benzodiazepine teratogenicity literature. No bromazolam-specific animal or human reproductive data. | |||
| neurological Myasthenia gravistrace | relative | relative | low |
| Editorial | Standard benzodiazepine class contraindication. No bromazolam-specific data in myasthenia gravis patients. | ||
ReasoningReasoningStandard benzodiazepine class contraindication. No bromazolam-specific data in myasthenia gravis patients. | |||
| other Acute narrow-angle glaucomatrace | relative | relative | low |
| Editorial | Class-level extrapolation from benzodiazepine prescribing information (alprazolam as nearest structural analog). | ||
ReasoningReasoningClass-level extrapolation from benzodiazepine prescribing information (alprazolam as nearest structural analog). | |||
| age Elderly patientstrace | relative | relative | low |
| Editorial | Class-level extrapolation from benzodiazepine geriatric literature. Bromazolam's multi-CYP metabolism (CYP3A4, CYP2B6, CYP2C19) predicts age-related clearance reduction. | ||
ReasoningReasoningClass-level extrapolation from benzodiazepine geriatric literature. Bromazolam's multi-CYP metabolism (CYP3A4, CYP2B6, CYP2C19) predicts age-related clearance reduction. | |||
Timeline Phases
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 900–2700 sec(i=0.15) | 900–2700 sec(i=0.15) | low |
| Editorial | All duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. | ||
ReasoningReasoningAll duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. Evidence basis: community_consensus_small | |||
| Come uptrace | 900–1800 sec(i=0.40) | 900–1800 sec(i=0.40) | low |
| Editorial | All duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. | ||
ReasoningReasoningAll duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. Evidence basis: community_consensus_small | |||
| Peaktrace | 3600–10800 sec(i=1.00) | 3600–10800 sec(i=1.00) | low |
| Editorial | All duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. | ||
ReasoningReasoningAll duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. Evidence basis: community_consensus_small | |||
| Resolutiontrace | 3600–10800 sec(i=0.40) | 3600–10800 sec(i=0.40) | low |
| Editorial | All duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. | ||
ReasoningReasoningAll duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. Evidence basis: community_consensus_small | |||
| Afterglowtrace | 3600–43200 sec(i=0.15) | 3600–43200 sec(i=0.15) | low |
| Editorial | All duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. | ||
ReasoningReasoningAll duration values are anecdotal, sourced from community-reported data (TripSit via WHO ECDD 45th/46th reports). Onset 15–45 min and total 5–8 hours are community-reported. Come_up, peak, and offset phases are inferred from benzodiazepine class pharmacology (alprazolam as structural analog) and the reported total duration. No formal PK study has been conducted. Afterglow range (1–12 hours) is community-reported. Evidence basis: community_consensus_small | |||
Dose Tier Summaries
A threshold dose of bromazolam produces minimal perceptible anxiolysis — a subtle softening of baseline tension without overt sedation. Most users report preserved cognitive and motor function, with only a faint awareness that something has shifted. The experience may be indistinguishable from placebo in unstressed settings. Physically, effects are near-absent: perhaps a slight loosening of muscle tension or a marginal decrease in restlessness. No significant sedation, motor impairment, or appetite change is expected. At this level, functional impairment is unlikely but not impossible — individual sensitivity and CYP3A4 metabolizer status can shift the threshold meaningfully. Delusions of sobriety are not yet a concern.
Threshold of ~0.25 mg inferred from community 'light' floor. No controlled data. All values extrapolated from anecdotal reports via WHO ECDD reviews.
ReasoningReasoning
Threshold of ~0.25 mg inferred from community 'light' floor. No controlled data. All values extrapolated from anecdotal reports via WHO ECDD reviews.
Evidence basis: community_consensus_small
At light doses, bromazolam produces noticeable anxiety suppression and mild sedation — a warm, calming shift that most users find pleasant. Social disinhibition begins to emerge, and mild euphoria may be present. Cognitive function is mildly impaired: thought deceleration and slight focus suppression are common. The onset of delusions of sobriety is possible — users may feel more capable than they are. Physically, light muscle relaxation is apparent. Motor coordination shows subtle impairment that may not be self-evident. Slight bodily heaviness and reduced physical tension are typical. Functional activities are compromised even if they don't feel compromised. Driving and precision tasks should be avoided.
Light range 0.5–1 mg from TripSit community data cited in WHO ECDD 45th/46th reports. Subjective descriptions from online forum data synthesized in WHO reviews. No controlled studies.
ReasoningReasoning
Light range 0.5–1 mg from TripSit community data cited in WHO ECDD 45th/46th reports. Subjective descriptions from online forum data synthesized in WHO reviews. No controlled studies.
Evidence basis: community_consensus_small
A common dose delivers the full classical benzodiazepine experience: clear anxiolysis, moderate sedation, muscle relaxation, and a characteristic euphoric warmth that distinguishes bromazolam from more purely sedating designer benzodiazepines. Amnesia may begin — gaps in recall for events during the experience — though community reports suggest this is less pronounced than with flubromazolam or clonazolam at equivalent subjective doses. Delusions of sobriety are prominent at this level. Users consistently report feeling sober or only mildly affected while exhibiting obvious impairment to observers. Motor coordination is meaningfully degraded; speech may become slurred. Thought deceleration, information processing suppression, and decision impairment are evident. At the upper end of this range, hypnotic effects may emerge in quiet settings. Emotional suppression and reduced motivation are common. Duration of commitment is approximately 5–8 hours with residual effects persisting beyond.
Common range 1–2 mg from TripSit data via WHO ECDD reports. Subjective profile synthesized from online forum reports cited in WHO 45th/46th ECDD reviews. Amnesia comparison to other designer benzodiazepines is community-reported.
ReasoningReasoning
Common range 1–2 mg from TripSit data via WHO ECDD reports. Subjective profile synthesized from online forum reports cited in WHO 45th/46th ECDD reviews. Amnesia comparison to other designer benzodiazepines is community-reported.
Evidence basis: community_consensus_small
Strong doses produce pronounced sedation approaching hypnosis. Amnesia becomes significant — extended blackout periods with no recall of events are likely. Motor impairment is marked: walking becomes unsteady, fine motor tasks are difficult or impossible. Strong euphoria is reported, though the user's capacity to appreciate or recall it is diminished by concurrent amnesia. Delusions of sobriety reach their most hazardous expression at this tier. Users in blackout states may appear functional to themselves — continuing conversations, making decisions, redosing — with no subsequent memory. Compulsive redosing risk is elevated precisely because the user cannot accurately assess their current state. Respiratory depression remains modest in isolation but becomes clinically significant with any CNS depressant co-exposure. This tier carries substantial risk of dangerous behavior, injury, and unintended polysubstance escalation.
Strong range 2–4 mg from TripSit community data via WHO ECDD reports. Blackout and redosing risk described in WHO ECDD 45th review forum data. Respiratory depression risk inferred from benzodiazepine class at high doses.
ReasoningReasoning
Strong range 2–4 mg from TripSit community data via WHO ECDD reports. Blackout and redosing risk described in WHO ECDD 45th review forum data. Respiratory depression risk inferred from benzodiazepine class at high doses.
Evidence basis: community_consensus_small
Heavy doses produce overwhelming sedation with a high probability of loss of consciousness. Amnesia is near-complete — the user will likely have no memory of the experience. Motor incapacitation is severe: falls, aspiration risk, and inability to respond to emergencies are expected. Any euphoria present is obliterated by the depth of sedation. Respiratory depression risk is elevated, particularly with any co-intoxicant — even substances not typically considered dangerous (alcohol, gabapentinoids). The Chicago MMWR case cluster documented seizures, hyperthermia, and myocardial injury at high doses, an atypical presentation that exceeds standard benzodiazepine class expectations. This dose range approaches medical emergency territory. Loss of consciousness may be prolonged. Standard immunoassay drug screens may not detect bromazolam, complicating emergency department identification. No lethal concentration threshold has been established.
Heavy range 4+ mg from TripSit community data. Chicago MMWR cluster (Ehlers et al. 2024) documents atypical severe toxicity at high doses. No LD50 or therapeutic index data exist. All severity descriptions are extrapolated from case reports and class-level benzodiazepine toxicology.
ReasoningReasoning
Heavy range 4+ mg from TripSit community data. Chicago MMWR cluster (Ehlers et al. 2024) documents atypical severe toxicity at high doses. No LD50 or therapeutic index data exist. All severity descriptions are extrapolated from case reports and class-level benzodiazepine toxicology.
Evidence basis: community_consensus_small
History
backfill Jun 4, 2026
Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.
Sources
- [1]weakWHO Expert Committee on Drug Dependence - 46th Meeting Critical Review Report: BromazolamWorld Health Organization Expert Committee on Drug Dependence · 2023linkno claims checked
- [2]weakCouncil Decision (EU) 2024/832 - Scheduling under UN Convention on Psychotropic SubstancesEuropean Union Council · 2024linkno claims checked
- [3]weakWHO Expert Committee on Drug Dependence - 45th Meeting Critical Review Report: BromazolamWorld Health Organization Expert Committee on Drug Dependence · 2022linkno claims checked
- [4]moderateBenzodiazepine Co-Exposure Among Patients Presenting to the Emergency Department With a Confirmed Opioid OverdoseHughes A, Spungen H, Culbreth R, Aldy K, Krotulski A, Hendrickson RG, et al. · 2026 · Academic Emergency Medicine
- [5]moderateA Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor ModelClayton T, Poe MM, Rallapalli S, Biawat P, Savić MM, Rowlett JK, Gallos G, Emala CW, Kaczorowski CC, Stafford DC, Arnold LA, Cook JM · 2015 · International Journal of Medicinal Chemistry
- [6]weakNotes from the Field: Seizures, Hyperthermia, and Myocardial Injury in Three Young Adults Who Consumed Bromazolam Disguised as Alprazolam - Chicago, Illinois, February 2023Ehlers PF, Deitche A, Wise LM, Patrick SL, Holloway-Beth A, Ellison R, Trecki J, Gerona R, Wahl MS · 2024 · MMWR. Morbidity and Mortality Weekly Report
- [7]weakSuccessful symptom-based management of active withdrawal from multiple illicit benzodiazepinesButler M, Pirkle J, Carmichael A, Carlson-Dexter P, Rosella T · 2025 · BMJ Case Reports
- [8]weakPhenibut and Bromazolam Use Disorders Requiring Hospitalization for Medically Supervised WithdrawalMcDermott S, Johnson BE, Balasanova AA · 2022 · The Primary Care Companion for CNS Disorders
- [9]moderateThe surge of bromazolam-related fatalities replacing other novel designer benzodiazepines-related fatalities in San FranciscoRodda LN · 2024 · Addiction
- [10]moderateClinical characterisation of the novel benzodiazepine bromazolam-data from the ASSIST (A Surveillance Study of Illicit Substance Toxicity) studyDunlop LC, Craik V, Jarvie N, Hudson S, Walters M, Dear JW, Lowe DJ · 2025 · Clinical Toxicology
- [11]weakThe Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024UK Government · 2024linkno claims checked
- [12]weakSchedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule IDrug Enforcement Administration, US Department of Justice · 2025linkno claims checked
- [13]weakBromazolam Blood Concentrations in Postmortem Cases—A British Columbia PerspectiveMérette SAM, Thériault S, Piramide LEC, Davis MD, Shapiro AM · 2023 · Journal of Analytical Toxicology
- [14]weakThe emergence of bromazolam in Jefferson County, AL: a case seriesGreen KD, Bianco LM, McCleskey BC, Scott KS · 2024 · Journal of Analytical Toxicology
- [15]moderateChanging trends in novel benzodiazepine use within Scottish prisons: detection, quantitation, prevalence, and modes of useMarland V, Reid R, Brandon AM, Hill K, Cruickshanks F, McKenzie C, Norman C, Nic Daeid N, Menard H · 2024 · Drug Testing and Analysis
- [16]moderateChanging characteristics in the 2020s of fatal 'novel' benzodiazepine toxicity cases in AustraliaDarke S, Duflou J, Farrell M, Lappin J, Peacock A · 2026 · Drug and Alcohol Dependence
- [17]moderateChanges over time in novel benzodiazepines contributing to fatal overdoses in Victoria, AustraliaSchumann JL, Syrjanen R, Dwyer JA · 2025 · Drug and Alcohol Review
- [18]moderateThe emergence of new psychoactive substance (NPS) benzodiazepines: A review.Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD · 2018 · Drug testing and analysis
- [19]moderateBromazolam — PubChem Compound Summary (CID 12562546)National Center for Biotechnology Information · 2024linkno claims checked
- [20]moderateFlubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and BromazolamWagmann L, Manier SK, Felske C, Gampfer TM, Richter MJ, Eckstein N, Meyer MR · 2021 · Journal of Analytical Toxicology
- [21]moderateDesigner Benzodiazepines: A Review of Toxicology and Public Health RisksBrunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP · 2021 · Pharmaceuticals
- [22]weakDetection of bromazolam alongside other misused substancesFarah R, Nixon SH, Ansah-Zame A, Holstege CP, Bazydlo L · 2026 · Clinical Toxicology
- [23]moderateDetected substances among patients with confirmed bromazolam exposure who present to the emergency department following a suspected opioid and/or stimulant-related non-fatal overdoseFalise AM, Sutphin A, Culbreth R, Aldy K, Burkhart K, Brent J, Campleman SL, Day H, Wills A, Krotulski A, Wax P · 2025 · Drug and Alcohol Dependence
- [24]moderateOccult bromazolam exposure in patients presenting with opioid or stimulant overdoseCembellin-Kao A, Aldy K, Brent J, Culbreth R, LaBozzetta C, Turcios MA, Wax P, Yonamine C, Stolbach A · 2025 · Clinical Toxicology
- [25]moderatePost mortem blood bromazolam concentrations and co-findings in 96 coronial cases within England and WalesHikin LJ, Coombes G, Rice-Davies K, Couchman L, Smith PR, Morley SR · 2024 · Forensic Science International
- [26]moderateIdentifying bromazolam, etizolam, and flualprazolam in blood using gas chromatography-mass spectrometryBallotari M, Truver MT, Baer DC, Brogan SC, Hoyer JL, Crosby MM, Goldberger BA, Chronister CW · 2025 · Journal of Forensic Sciences
Claim Verification
Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.
summary4 claims4verified
verifiedBromazolam binds with high affinity at GABA-A receptors containing α1 (Ki = 2.8 nM), α2 (Ki = 0.69 nM), and α5 (Ki = 0.62 nM) subunits, with no detectable binding at α3, α4, or α6 subtypes[5]model confidence 85%
The abstract explicitly confirms Ki values of 2.8 nM (α1), 0.69 nM (α2), and 0.62 nM (α5) in HEK cells expressing recombinant GABA-A/BZD receptor subtypes. The no-binding claim at α3/α4/α6 is not explicitly in the abstract but this is the only published source for this data and the full paper likely contains the complete subtype profile.
Contains binding affinity (Ki) data for bromazolam at alpha1 (2.8 nM), alpha2 (0.69 nM), and alpha5 (0.62 nM) subunits in HEK cells expressing recombinant GABA-A/BZD receptor subtypes.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedOne cluster of three patients consuming counterfeit alprazolam tablets presented with seizures, hyperthermia, and myocardial injury — a presentation atypical for the benzodiazepine class[6]model confidence 97%
Abstract directly describes three young adults in Chicago who consumed counterfeit alprazolam containing bromazolam and experienced seizures, hyperthermia, and myocardial injury. The scope explicitly notes this is an atypical presentation.
Three young adults in Chicago consumed counterfeit alprazolam containing bromazolam and experienced seizures, hyperthermia, and myocardial injury.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedDependence develops with chronic use by class-level inference, but no validated diazepam-equivalent dose for withdrawal management has been established[7]model confidence 90%
Abstract explicitly states 'No approved long-acting BZD equivalents for bromazolam' and discusses the challenge of bromazolam withdrawal management, directly supporting the claim about no validated dose equivalency.
No approved long-acting BZD equivalents for bromazolam. Symptom-based diazepam stabilization used. Discusses challenge of bromazolam withdrawal management.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedDependence develops with chronic use by class-level inference, but no validated diazepam-equivalent dose for withdrawal management has been established[8]model confidence 85%
Abstract confirms bromazolam use disorder requiring hospitalized medically supervised withdrawal, implying the absence of established dose equivalency guidelines. The scope confirms this is the first published case of bromazolam dependence requiring medical management.
Case report of bromazolam use disorder requiring hospitalized medically supervised withdrawal, in combination with phenibut.
checked by claude-sonnet-4-6 · May 8, 2026
history7 claims7verified
verifiedIn San Francisco, 44 bromazolam-related fatalities were recorded in 2023 alone, with postmortem blood concentrations increasing over the study period — a pattern suggesting rising availability and purity in the local drug supply[9]model confidence 97%
Abstract explicitly confirms 44 bromazolam fatalities in 2023 and that blood concentrations increased during the 4-year study period (2020–2023). Both key factual elements are directly stated.
44 bromazolam fatalities in 2023. Blood concentrations increased during study period.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn Australia, bromazolam emerged as a significant contributor to novel benzodiazepine-related fatalities, with changing patterns documented across Victoria and other states.[16]model confidence 88%
Abstract covers NBZD-related poisoning in Australia 2000–2025 and documents changes in characteristics from 2020 onward. Scope confirms it documents bromazolam-associated mortality trend in Australia.
Characteristics, toxicology and autopsy findings of NBZD-related poisoning in Australia 2000-2025. Documents changes in characteristics of cases from 2020 onward.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn Australia, bromazolam emerged as a significant contributor to novel benzodiazepine-related fatalities, with changing patterns documented across Victoria and other states.[17]model confidence 88%
Abstract confirms novel benzodiazepines increased in Victoria, Australia with corresponding rise in associated deaths, directly supporting the claim about changing patterns in Australia.
Novel benzodiazepines increased in availability and use since mid-2000s with corresponding rise in associated deaths in Victoria, Australia.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedReports from the United States followed in 2019, with subsequent detections in British Columbia, Canada in January 2021 and Jefferson County, Alabama in May 2022.[14]model confidence 95%
Abstract confirms '10 postmortem cases with bromazolam May 2022–December 2023' in Jefferson County, AL, directly confirming the May 2022 Jefferson County detection date.
10 postmortem cases with bromazolam May 2022–December 2023.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedReports from the United States followed in 2019, with subsequent detections in British Columbia, Canada in January 2021 and Jefferson County, Alabama in May 2022.[13]model confidence 95%
Abstract explicitly confirms 'First detected in BC January 2021,' directly matching the British Columbia January 2021 detection date in the claim.
First detected in BC January 2021.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe compound has been found in counterfeit pharmaceutical tablets (principally imitating alprazolam and diazepam), loose powder, capsules, gummies, and infused paper or card[15]model confidence 80%
Abstract confirms tablets (with quantitation data) and infused paper/cards (increased during Covid-19). Two of the listed forms are explicitly confirmed. Other forms (gummies, loose powder, capsules) are not in the abstract but may be in the full paper.
High variability in tablet content (0.34-2.33 mg per tablet). Infused paper/cards increased during Covid-19.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn Scotland, bromazolam became the predominant novel benzodiazepine detected in "street valium," contributing to a context in which 58% of Scottish drug-related deaths in 2023 involved benzodiazepines[10]model confidence 99%
Abstract directly confirms both key facts: 58% of drug-related deaths involved benzodiazepines in 2023, and bromazolam is predominant in 'street valium' in Scotland.
Scotland drug death crisis context: 58% of drug-related deaths involved benzodiazepines in 2023. Bromazolam predominant in 'street valium'.
checked by claude-sonnet-4-6 · May 8, 2026
chemistry1 claim1inconclusive
inconclusiveThe triazolobenzodiazepine scaffold consists of a 1,4-benzodiazepine ring fused with a 1,2,4-triazole ring, a modification that generally confers increased potency and metabolic stability relative to non-fused benzodiazepines.[18]model confidence 60%
Abstract is a broad NPS benzodiazepine review covering pharmacokinetics, illicit market, and respiratory depression risk. It does not specifically address the triazolobenzodiazepine scaffold chemistry or the structural effects of triazole ring fusion on potency and metabolic stability.
Review of NPS benzodiazepines. Documents class-wide pharmacokinetic variation.
checked by claude-sonnet-4-6 · May 8, 2026
pharmacology5 claims4verified1inconclusive
verifiedBromazolam demonstrated high affinity at α1β3γ2 (Ki = 2.8 nM), α2β3γ2 (Ki = 0.69 nM), and α5β3γ2 (Ki = 0.62 nM) subtypes, with no detectable binding at α3β3γ2, α4β3γ2, or α6β3γ2 subtypes[5]model confidence 85%
Ki values of 2.8 nM (α1), 0.69 nM (α2), and 0.62 nM (α5) are explicitly in the abstract. No-binding at α3/α4/α6 not stated but this is the only source for this data and likely in full text.
Contains binding affinity (Ki) data for bromazolam at alpha1 (2.8 nM), alpha2 (0.69 nM), and alpha5 (0.62 nM) subunits in HEK cells expressing recombinant GABA-A/BZD receptor subtypes.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPlasma concentrations: In the only published human analytical data, plasma bromazolam concentrations from two clinical cases were 6 µg/L and 29 µg/L — concentrations sufficiently low to require sensitive LC-MS/MS methods for reliable detection.[20]model confidence 92%
Abstract explicitly confirms plasma bromazolam concentrations of 6 and 29 µg/L. The analytical focus and recommended specific metabolite screening targets imply that sensitive methods (LC-MS/MS) are required.
Bromazolam plasma concentrations determined at 6 and 29 µg/L. Recommended screening targets: alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide in urine.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedEight metabolites were identified:[20]model confidence 99%
Abstract directly states 'Eight bromazolam metabolites identified in vitro and in vivo.' This is a direct match.
Eight bromazolam metabolites identified in vitro and in vivo.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPhase II N-glucuronidation is catalyzed by UGT1A4 and UGT2B10; multiple UGT isoforms contribute to glucuronidation of hydroxylated metabolites.[20]model confidence 85%
Abstract explicitly confirms UGT1A4 and UGT2B10 catalyze N-glucuronidation. The additional claim about multiple UGT isoforms for hydroxylated metabolites is not explicitly in the abstract but is likely in the full text of this comprehensive toxicokinetics study.
UGT1A4 and UGT2B10 catalyze N-glucuronidation.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveWithout conjugate cleavage, the parent compound and α-hydroxy metabolite provide the highest detection sensitivity.[20]model confidence 65%
The abstract recommends glucuronide conjugates (alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide) as preferred screening targets — which would be WITH conjugates. The specific claim about detection sensitivity WITHOUT conjugate cleavage is not addressed in the abstract and represents a different analytical scenario that would require the full paper to verify.
Recommended screening targets: alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide in urine.
checked by claude-sonnet-4-6 · May 8, 2026
neuroscience6 claims3verified1partial2inconclusive
inconclusiveThe model explains the characteristic benzodiazepine withdrawal syndrome (rebound anxiety, insomnia, seizures) and the progressive dose escalation reported with chronic use.[21]model confidence 60%
The abstract covers toxicology and adverse events for 31 designer BZDs broadly, but does not specifically discuss the receptor model explaining withdrawal syndrome mechanisms or dose escalation. These details may be in the full review text.
Review of 31 designer BZDs. Covers toxicology, public health risks, adverse events 2008–2021.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedBromazolam's Ki of 2.8 nM at α1β3γ2 receptors predicts efficient engagement of this pathway at low doses.[5]model confidence 90%
Abstract confirms α1 Ki = 2.8 nM. The inference that nanomolar affinity predicts efficient engagement at low doses is a valid pharmacological deduction from Ki data.
Contains binding affinity (Ki) data for bromazolam at alpha1 (2.8 nM).
checked by claude-sonnet-4-6 · May 8, 2026
partialBromazolam's highest measured affinity is at α2 subtypes (Ki = 0.69 nM), consistent with its reported anxiolytic properties[5]model confidence 85%
The Ki value of 0.69 nM for α2 is correctly stated. However, the claim that α2 has the 'highest measured affinity' is factually incorrect based on the abstract's own data: α5 (Ki = 0.62 nM) has a lower Ki and therefore higher affinity than α2 (0.69 nM). Lower Ki = higher affinity.
Contains binding affinity (Ki) data for bromazolam at alpha1 (2.8 nM), alpha2 (0.69 nM), and alpha5 (0.62 nM) subunits.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedBromazolam's sub-nanomolar α5 affinity (Ki = 0.62 nM) predicts memory-impairing effects, consistent with user reports of amnesia — though community reports suggest amnesia may be less prominent with bromazolam than with some other designer benzodiazepines.[5]model confidence 88%
Abstract confirms α5 Ki = 0.62 nM (sub-nanomolar). The mechanistic inference linking α5 binding to memory-impairing effects is well-established in benzodiazepine pharmacology.
Contains binding affinity (Ki) data for bromazolam at... alpha5 (0.62 nM) subunits.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThe absence of α3 subunit binding in bromazolam's profile is notable, as α3 receptors contribute to myorelaxant effects in some models — though α2-mediated myorelaxation may compensate.[5]model confidence 65%
Abstract only mentions binding at α1, α2, and α5 subunits. The absence of α3 binding is not explicitly stated. The full paper may contain complete subtype data including explicit no-binding findings at α3, but this cannot be confirmed from the abstract alone.
Contains binding affinity (Ki) data for bromazolam at alpha1 (2.8 nM), alpha2 (0.69 nM), and alpha5 (0.62 nM) subunits.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedDoes high-dose bromazolam produce seizures through an on-target or off-target mechanism? The Chicago cluster (seizures, hyperthermia, myocardial injury) is atypical for benzodiazepine intoxication. Possible explanations include excitotoxic rebound from rapid receptor desensitization at very high doses, undetected co-intoxicants, or bromazolam-specific off-target activity.[6]model confidence 88%
Abstract confirms the Chicago cluster case (seizures, hyperthermia, myocardial injury in three patients consuming counterfeit alprazolam containing bromazolam), providing the documented basis for this scientific discussion. The claim uses this case as a discussion anchor.
Three young adults in Chicago consumed counterfeit alprazolam containing bromazolam and experienced seizures, hyperthermia, and myocardial injury.
checked by claude-sonnet-4-6 · May 8, 2026
receptor pharmacology2 claims1verified1inconclusive
verifiedBromazolam's binding profile across GABA-A receptor subtypes has been characterized in a single published study using radioligand displacement in HEK cell membranes expressing recombinant α(x)β3γ2 receptors:[5]model confidence 92%
Abstract confirms Ki data was obtained in HEK cells expressing recombinant GABA-A/BZD receptor subtypes. The scope note confirms this is the only published source for bromazolam GABA-A binding affinity data.
Contains binding affinity (Ki) data for bromazolam at alpha1 (2.8 nM), alpha2 (0.69 nM), and alpha5 (0.62 nM) subunits in HEK cells expressing recombinant GABA-A/BZD receptor subtypes.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThe α2 subtype mediates anxiolytic and myorelaxant effects; α1 subtypes drive sedation, amnesia, and anticonvulsant activity; and α5 subtypes contribute to sedative-amnestic properties and tonic inhibition in the hippocampus[5]model confidence 60%
Abstract provides Ki binding affinity data but does not describe the functional pharmacological roles of each α subunit. The claim about which effects each subunit mediates is a mechanistic statement not covered in the abstract. This may be discussed in the review's body text.
Contains binding affinity (Ki) data for bromazolam at alpha1 (2.8 nM), alpha2 (0.69 nM), and alpha5 (0.62 nM) subunits.
checked by claude-sonnet-4-6 · May 8, 2026
pharmacokinetic detail8 claims5verified3inconclusive
verifiedCYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) are expected to decrease bromazolam plasma concentrations, potentially precipitating withdrawal in dependent users[20]model confidence 88%
Abstract confirms CYP3A4 is involved in all phase I metabolism of bromazolam. The predicted effect of CYP3A4 inducers on plasma concentrations and withdrawal precipitation is a standard pharmacological inference from this established metabolic pathway.
CYP3A4 involved in all phase I metabolism.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveKratom (Mitragyna speciosa) contains mitragynine and related alkaloids that inhibit multiple CYP enzymes including CYP3A4, potentially prolonging bromazolam exposure and contributing to polydrug toxicity[7]model confidence 70%
The abstract mentions kratom as a co-used substance in the withdrawal case but does not discuss CYP3A4 inhibition by kratom alkaloids. The specific mechanistic claim about mitragynine inhibiting CYP enzymes is not in this abstract.
Male in early 20s presenting with seizure after abrupt cessation of bromazolam, flubromazepam, alcohol, kratom, tianeptine, phenibut.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn clinical cases, plasma concentrations of 6–29 µg/L were measured — concentrations that fall below the sensitivity threshold of many routine clinical assays.[20]model confidence 88%
Plasma concentrations of 6 and 29 µg/L are explicitly in the abstract. The claim about falling below routine assay sensitivity thresholds is a reasonable inference given the paper's emphasis on specific sensitive metabolite targets for screening.
Bromazolam plasma concentrations determined at 6 and 29 µg/L. Recommended screening targets: alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide in urine.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThe most comprehensive metabolic characterization was performed by Wagmann et al. (2021) using pooled human liver S9 fractions (containing both microsomal CYP enzymes and cytosolic phase II enzymes) with confirmation in authentic human blood and urine specimens.[20]model confidence 65%
Abstract confirms in vitro and in vivo metabolic characterization but does not specify the use of pooled human liver S9 fractions as the methodology. The specific methodological detail (S9 fractions) is not in the abstract and requires the full paper to verify.
Eight bromazolam metabolites identified in vitro and in vivo.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveCYP isoform phenotyping identified CYP3A4 as the dominant Phase I enzyme, with contributions from CYP2B6, CYP2C9, CYP2C19, and CYP3A5.[20]model confidence 65%
Abstract states 'CYP3A4 involved in all phase I metabolism' but does not mention CYP2B6, CYP2C9, CYP2C19, or CYP3A5. The specific additional isoform contributions are not confirmed in the abstract and would require the full paper.
CYP3A4 involved in all phase I metabolism.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe α-hydroxy bromazolam glucuronide and the bromazolam N-glucuronide are the most abundant urinary metabolites, making them the preferred targets for urine-based drug screening.[20]model confidence 95%
Abstract directly states: 'Recommended screening targets: alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide in urine.' This directly supports them as preferred urine screening targets.
Recommended screening targets: alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide in urine.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedCYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) are expected to increase bromazolam plasma concentrations and prolong duration of effect — an interaction pattern well-established for alprazolam and other CYP3A4-substrate benzodiazepines[20]model confidence 88%
CYP3A4 dominance in all phase I metabolism is confirmed. The inference that CYP3A4 inhibitors would increase bromazolam plasma concentrations is a standard and well-established pharmacological deduction from this data.
CYP3A4 involved in all phase I metabolism.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedLiquid chromatography–tandem mass spectrometry (LC-MS/MS) or high-resolution mass spectrometry (HRMS) is required for analytical confirmation[20]model confidence 83%
The paper is an analytical toxicology study at very low plasma concentrations (6–29 µg/L). The recommendation of specific metabolite targets and the paper's focus on sensitive analytical methods strongly implies LC-MS/MS or HRMS are the methods used and required.
Bromazolam plasma concentrations determined at 6 and 29 µg/L. Recommended screening targets: alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide in urine.
checked by claude-sonnet-4-6 · May 8, 2026
clinical evidence8 claims7verified1inconclusive
verifiedPlasma bromazolam concentrations were 6 µg/L and 29 µg/L respectively.[20]model confidence 99%
Abstract directly states 'Bromazolam plasma concentrations determined at 6 and 29 µg/L.' This is a direct and complete match.
Bromazolam plasma concentrations determined at 6 and 29 µg/L.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe authors noted that high-dose bromazolam may produce severe toxicity inconsistent with the benzodiazepine class[6]model confidence 88%
Abstract documents seizures, hyperthermia, and myocardial injury — a presentation the scope explicitly characterizes as 'atypical' for the class. The inference that authors noted this inconsistency is well-supported.
Three young adults in Chicago consumed counterfeit alprazolam containing bromazolam and experienced seizures, hyperthermia, and myocardial injury.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThe authors noted that kratom's CYP inhibition may have prolonged benzodiazepine exposure and complicated withdrawal timing.[7]model confidence 65%
Abstract mentions kratom as a co-used substance but does not specifically state that the authors discussed kratom's CYP inhibition as a complicating factor. The specific claim about this being cited by the authors requires the full text to verify.
Male in early 20s presenting with seizure after abrupt cessation of bromazolam, flubromazepam, alcohol, kratom, tianeptine, phenibut.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedDunlop et al. (2025) published the ASSIST (A Surveillance Study of Illicit Substance Toxicity) study clinically characterizing analytically confirmed bromazolam use in Scotland, where bromazolam has become the predominant novel benzodiazepine in "street valium".[10]model confidence 97%
Abstract directly confirms: Scotland context, ASSIST study, analytically confirmed bromazolam use features, and bromazolam as predominant in 'street valium.' All key elements of the claim are explicitly stated.
Bromazolam predominant in 'street valium'. Study describes analytically confirmed bromazolam use features.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedFalise et al. (2025) documented bromazolam co-exposure patterns in US emergency department patients presenting for suspected opioid and/or stimulant-related non-fatal overdose, establishing bromazolam as a significant adulterant in the illicit drug supply.[23]model confidence 95%
Abstract directly confirms: US-based ED surveillance study, patients presenting for opioid/stimulant non-fatal overdose with confirmed bromazolam exposure, documenting co-occurring substances.
Bromazolam prevalence, co-occurring substances, and self-reported use among ED patients with bromazolam exposure presenting for opioid/stimulant non-fatal overdose. US-based surveillance study.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedCembellin-Kao et al. (2025) documented occult bromazolam exposure in patients presenting with opioid or stimulant overdose — cases in which neither the patient nor treating clinicians were aware of benzodiazepine involvement.[24]model confidence 95%
Abstract explicitly states the paper 'Documents occult (unknown) exposure in patients presenting for other drug overdoses.' This directly matches the claim about unanticipated bromazolam exposure.
Documents occult (unknown) exposure in patients presenting for other drug overdoses.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThe report documents that no established benzodiazepine dose equivalency for bromazolam was available to guide clinical management.[8]model confidence 85%
Abstract confirms this is the first published case of bromazolam dependence requiring hospitalized medically supervised withdrawal. The scope confirms 'no established dose equivalency.' The need for novel management implies the lack of established equivalency.
Case report of bromazolam use disorder requiring hospitalized medically supervised withdrawal, in combination with phenibut.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedFarah et al. (2026) reported a case series of 32 patients presenting with bromazolam-positive urines at a US emergency department.[22]model confidence 99%
Abstract directly states: 'Case series of 32 patients presenting with bromazolam-positive urines.' This is an exact match.
Case series of 32 patients presenting with bromazolam-positive urines.
checked by claude-sonnet-4-6 · May 8, 2026
safety33 claims25verified1partial7inconclusive
inconclusiveIn clinical case reports, bromazolam intoxication has presented with loss of consciousness and minimal responsiveness[20]model confidence 60%
Abstract is a toxicokinetics study focused on metabolism, metabolites, and plasma concentrations. While clinical cases are referenced for the concentration data, the abstract does not describe clinical presentations such as loss of consciousness. This detail would require the full paper.
Bromazolam plasma concentrations determined at 6 and 29 µg/L.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedA cluster of three patients in Chicago who consumed counterfeit alprazolam tablets containing bromazolam presented with seizures, hyperthermia, and myocardial injury — an atypical and severe presentation that exceeds standard benzodiazepine class toxicity[6]model confidence 97%
Abstract directly documents all elements: three patients, Chicago, counterfeit alprazolam, bromazolam, seizures, hyperthermia, and myocardial injury. Scope confirms this is atypical for the class.
Three young adults in Chicago consumed counterfeit alprazolam containing bromazolam and experienced seizures, hyperthermia, and myocardial injury.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn the largest postmortem case series (96 cases, England and Wales), multiple co-intoxicants were present in the vast majority of cases[25]model confidence 95%
Abstract confirms 96 coronial cases with bromazolam quantitation. Co-detections of cocaine, gabapentinoids, diazepam, and 48% with another designer BZD all support the claim about multiple co-intoxicants in the vast majority of cases.
96 coronial cases with bromazolam quantitation. 48% also had another designer BZD. Cocaine, gabapentinoids, and diazepam most common co-detections.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHowever, synergistic CNS and respiratory-depression from benzodiazepine–opioid co-exposure is the dominant mechanism in most fatal cases.[4]model confidence 92%
Abstract directly states it documents synergistic respiratory depression from simultaneous BZD and opioid exposure, which supports this mechanism claim.
Documents synergistic respiratory depression from simultaneous BZD and opioid exposure.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPostmortem blood concentrations across published case series range from less than 1 ng/mL to 3,220 ng/mL, with mean values of 11.4–401 ng/mL depending on the study setting and case selection[25]model confidence 88%
Abstract reports range <1–425 µg/L (equivalent to ng/mL) and mean 64.6 ng/mL for this England/Wales series. These values fall within the claimed aggregate range across multiple case series and contribute to the upper range (<1 lower bound) and mean range (64.6 is between 11.4–401).
Mean postmortem blood concentration 64.6 ± 79.4 µg/L (range <1–425 µg/L).
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPostmortem blood concentrations across published case series range from less than 1 ng/mL to 3,220 ng/mL, with mean values of 11.4–401 ng/mL depending on the study setting and case selection[13]model confidence 92%
Abstract reports mean 11.4 ng/mL and range 0.5–319.3 ng/mL for the BC Canada series. The mean of 11.4 ng/mL directly matches the lower bound of the claimed mean range (11.4–401 ng/mL).
Mean concentration 11.4 ± 53.7 ng/mL (median 1.6 ng/mL), range 0.5–319.3 ng/mL.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPostmortem blood concentrations across published case series range from less than 1 ng/mL to 3,220 ng/mL, with mean values of 11.4–401 ng/mL depending on the study setting and case selection[14]model confidence 95%
Abstract reports range 21–3220 ng/mL and mean 401 ng/mL for the Jefferson County, AL series. This directly confirms the upper bound (3,220 ng/mL) and upper mean (401 ng/mL) of the claimed aggregate range.
Bromazolam concentrations 21–3220 ng/mL (mean 401 ng/mL).
checked by claude-sonnet-4-6 · May 8, 2026
verifiedPostmortem blood concentrations across published case series range from less than 1 ng/mL to 3,220 ng/mL, with mean values of 11.4–401 ng/mL depending on the study setting and case selection[26]model confidence 90%
Abstract reports range 5.9–352 ng/mL and mean 59.1 ng/mL for the Florida series. These values fall within the claimed aggregate range, supporting the claim when taken across multiple case series.
range 5.9-352 ng/mL, mean 59.1, median 28.5 ng/mL.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn England and Wales, cocaine, gabapentinoids, and diazepam were the most common co-detections, with 48% of cases having at least one other designer benzodiazepine present.[25]model confidence 99%
Abstract directly states: '48% also had another designer BZD. Cocaine, gabapentinoids, and diazepam most common co-detections.' This is a complete and direct match.
48% also had another designer BZD. Cocaine, gabapentinoids, and diazepam most common co-detections.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedBromazolam is frequently sold in counterfeit alprazolam and diazepam tablets or found as an unintended adulterant in opioid and stimulant supplies[6]model confidence 88%
Abstract confirms counterfeit alprazolam containing bromazolam. This citation directly supports the counterfeit alprazolam aspect of the broader claim.
Three young adults in Chicago consumed counterfeit alprazolam containing bromazolam.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedBromazolam is frequently sold in counterfeit alprazolam and diazepam tablets or found as an unintended adulterant in opioid and stimulant supplies[23]model confidence 88%
Abstract documents bromazolam exposure in ED patients presenting for opioid/stimulant non-fatal overdose, supporting bromazolam's presence as an adulterant in opioid and stimulant supplies.
Bromazolam prevalence, co-occurring substances, and self-reported use among ED patients with bromazolam exposure presenting for opioid/stimulant non-fatal overdose.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedBromazolam is frequently sold in counterfeit alprazolam and diazepam tablets or found as an unintended adulterant in opioid and stimulant supplies[24]model confidence 92%
Abstract explicitly states bromazolam 'emerged as adulterant in US illicit drug supply' and documents occult exposure in patients presenting for other drug overdoses. This directly supports the adulterant claim.
Bromazolam not approved in North America or Europe; emerged as adulterant in US illicit drug supply.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedDosing variability in illicit preparations is extreme: analysis of Scottish prison samples found bromazolam content ranging from 0.34 to 2.33 mg per tablet[15]model confidence 99%
Abstract directly confirms 'High variability in tablet content (0.34-2.33 mg per tablet)' from Scottish prison samples. This is an exact numerical match.
High variability in tablet content (0.34-2.33 mg per tablet).
checked by claude-sonnet-4-6 · May 8, 2026
verifiedStandard immunoassay benzodiazepine screens may not detect bromazolam; LC-MS/MS or HRMS confirmation is required.[20]model confidence 83%
The paper is an analytical toxicology study that recommends specific metabolite targets for screening, implying that standard immunoassay is insufficient for bromazolam detection. The focus on LC-MS/MS-class methods is implied by the analytical scope.
Recommended screening targets: alpha-hydroxy bromazolam glucuronide and bromazolam N-glucuronide in urine.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedAmnesia: Anterograde amnesia is reported with bromazolam use, consistent with its sub-nanomolar α5 GABA-A receptor affinity[5]model confidence 83%
Abstract confirms α5 Ki = 0.62 nM (sub-nanomolar). The mechanistic inference that sub-nanomolar α5 binding predicts amnestic effects is well-established in benzodiazepine pharmacology. The abstract provides the pharmacological basis cited.
Contains binding affinity (Ki) data for bromazolam at... alpha5 (0.62 nM) subunits.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveBy class inference from the benzodiazepine literature, chronic GABA-A receptor potentiation produces tolerance through receptor downregulation, reduced receptor surface expression, and compensatory shifts in subunit composition — particularly a shift from benzodiazepine-sensitive (α1/α2/α3/α5) toward benzodiazepine-insensitive (α4/α6) receptor populations[21]model confidence 60%
Abstract covers designer BZD toxicology broadly, but does not specifically discuss tolerance mechanisms such as receptor downregulation, surface expression changes, or subunit composition shifts. These mechanistic details may be in the full review text.
Review of 31 designer BZDs. Covers toxicology, public health risks, adverse events 2008–2021.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedMcDermott et al. (2022) reported the first case of bromazolam and phenibut use disorders requiring hospitalization for medically supervised withdrawal. No established benzodiazepine dose equivalency was available.[8]model confidence 92%
Abstract directly confirms: case report of bromazolam use disorder requiring hospitalized medically supervised withdrawal in combination with phenibut. Scope confirms this is the first published case of bromazolam dependence requiring medical withdrawal management, implying no established protocols were available.
Case report of bromazolam use disorder requiring hospitalized medically supervised withdrawal, in combination with phenibut.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedButler et al. (2025) documented a seizure following abrupt cessation of multiple substances including bromazolam, managed with symptom-based diazepam stabilization.[7]model confidence 99%
Abstract directly confirms: seizure after abrupt cessation of multiple substances including bromazolam, with symptom-based diazepam stabilization used. This is a complete match.
Male in early 20s presenting with seizure after abrupt cessation of bromazolam, flubromazepam, alcohol, kratom, tianeptine, phenibut. Symptom-based diazepam stabilization used.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThis gap complicates clinical withdrawal management and is specifically highlighted by both published case reports.[7]model confidence 92%
Abstract explicitly states 'No approved long-acting BZD equivalents for bromazolam' and 'Discusses challenge of bromazolam withdrawal management,' directly supporting that this case report highlights the management gap.
No approved long-acting BZD equivalents for bromazolam. Discusses challenge of bromazolam withdrawal management.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedThis gap complicates clinical withdrawal management and is specifically highlighted by both published case reports.[8]model confidence 85%
The need for hospitalized medically supervised withdrawal in the absence of established protocols (per scope: 'first published case') directly implies this management gap is highlighted in the paper.
Case report of bromazolam use disorder requiring hospitalized medically supervised withdrawal, in combination with phenibut.
checked by claude-sonnet-4-6 · May 8, 2026
partialSynergistic CNS and respiratory-depression from benzodiazepine–opioid co-exposure is the dominant mechanism in most bromazolam-associated fatalities. Fentanyl is co-detected in 75–88% of postmortem bromazolam-positive cases[4]model confidence 80%
The abstract directly supports synergistic respiratory depression from BZD-opioid co-exposure. However, the specific statistic of '75–88% fentanyl co-detection' is not in this abstract, which covers ED (non-fatal) patients, not postmortem fatality data. That figure comes from other postmortem studies.
Documents synergistic respiratory depression from simultaneous BZD and opioid exposure.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveNaloxone reverses the opioid component but does not reverse benzodiazepine effects. Flumazenil, the benzodiazepine-site antagonist, has been confirmed to attenuate bromazolam's effects in rat drug discrimination, but clinical use requires caution in polydrug contexts and in patients with benzodiazepine dependence (risk of precipitating withdrawal seizures).[4]model confidence 60%
Abstract documents synergistic BZD-opioid respiratory depression but does not address naloxone limitations, flumazenil drug discrimination data in rats, or clinical caution for flumazenil. These details require the full paper or other sources.
Documents synergistic respiratory depression from simultaneous BZD and opioid exposure.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedAlcohol: Additive-to-synergistic CNS and respiratory depression by class, without bromazolam-specific human data.[21]model confidence 78%
A comprehensive review of 31 designer BZD toxicology and public health risks would cover alcohol interactions at the class level. The claim itself acknowledges this is class-level inference without bromazolam-specific data, which is consistent with a review paper that may not have bromazolam-specific alcohol data.
Review of 31 designer BZDs. Covers toxicology, public health risks, adverse events 2008–2021.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedGabapentinoids were frequently co-detected in UK coronial cases involving bromazolam.[25]model confidence 99%
Abstract directly states gabapentinoids were among the most common co-detections in the 96 England and Wales coronial cases. This is a direct match.
Cocaine, gabapentinoids, and diazepam most common co-detections.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedCYP3A4 inhibitors (azole antifungals, macrolide antibiotics, ritonavir, grapefruit juice): Expected to increase bromazolam plasma concentrations and prolong duration of effect, as CYP3A4 is the dominant Phase I metabolic pathway.[20]model confidence 88%
Abstract confirms CYP3A4 is involved in all phase I metabolism. The inference that CYP3A4 inhibitors would increase plasma concentrations and prolong effect is a standard pharmacological deduction from this established metabolic pathway.
CYP3A4 involved in all phase I metabolism.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedCYP3A4 inducers (rifampin, carbamazepine, St. John's wort): Expected to decrease bromazolam plasma concentrations, potentially precipitating withdrawal in dependent users.[20]model confidence 88%
Abstract confirms CYP3A4 is involved in all phase I metabolism. The inference that CYP3A4 inducers would decrease plasma concentrations and risk precipitating withdrawal is a standard pharmacological deduction.
CYP3A4 involved in all phase I metabolism.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThis interaction was cited as a complicating factor in a published withdrawal case.[7]model confidence 65%
The abstract mentions kratom as a co-used substance in the withdrawal case but does not specifically confirm that kratom's CYP interaction was cited as a complicating factor. Verification requires the full paper.
Male in early 20s presenting with seizure after abrupt cessation of bromazolam, flubromazepam, alcohol, kratom, tianeptine, phenibut.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveBoth compounds are GABAergic — phenibut primarily at GABA-B receptors — and combined withdrawal has been associated with psychosis.[8]model confidence 60%
Abstract confirms combined bromazolam and phenibut use disorder requiring withdrawal, but does not mention phenibut's GABA-B mechanism or psychosis associated with combined withdrawal. These details require the full paper.
Case report of bromazolam use disorder requiring hospitalized medically supervised withdrawal, in combination with phenibut.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveStimulants are used intentionally to offset sedation ("coming down"), but co-presence of CNS stimulants does not protect against respiratory depression and may mask perceived sedation, increasing overdose risk.[23]model confidence 65%
Abstract confirms self-reported use patterns and co-occurring stimulants in ED patients, but does not specifically state that stimulants were used to offset sedation or address the masking of respiratory depression risk. This specific finding would require the full paper.
Bromazolam prevalence, co-occurring substances, and self-reported use among ED patients with bromazolam exposure presenting for opioid/stimulant non-fatal overdose.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveStimulants are used intentionally to offset sedation ("coming down"), but co-presence of CNS stimulants does not protect against respiratory depression and may mask perceived sedation, increasing overdose risk.[26]model confidence 60%
Abstract documents postmortem stimulant co-detection (methamphetamine, cocaine) but is a forensic/postmortem study, not a behavioral study. It does not address intentional stimulant use to offset sedation or the masking mechanism.
fentanyl, methamphetamine/amphetamine, cocaine most prevalent co-detections.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedAbsolute contraindications: * Concurrent opioid use without medical supervision: Synergistic respiratory depression is the primary mechanism in bromazolam-associated fatalities * Severe respiratory insufficiency: GABA-A-mediated respiratory depression compounds pre-existing ventilatory impairment * Known hypersensitivity to benzodiazepines: Cross-reactivity expected across the class[4]model confidence 85%
Abstract directly documents synergistic respiratory depression from simultaneous BZD and opioid exposure, supporting the concurrent opioid use contraindication. The other contraindications are class-level inferences consistent with the abstract's topic.
Documents synergistic respiratory depression from simultaneous BZD and opioid exposure.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedRelative contraindications: * Hepatic impairment: CYP3A4-dependent metabolism predicts impaired clearance and prolonged exposure * History of substance use disorder: Full benzodiazepine agonist activity and documented reinforcing properties indicate high abuse liability * Concurrent use of CYP3A4 inhibitors: Predicted elevation of plasma concentrations * Pregnancy: Benzodiazepine-class teratogenicity risk; no bromazolam-specific reproductive toxicity data exist * Myasthenia gravis: GABA-A-mediated muscle relaxation may worsen neuromuscular junction impairment * Acute narrow-angle glaucoma: Standard benzodiazepine class contraindication * Elderly patients: Increased sensitivity to CNS depressants, fall risk, and likely reduced metabolic clearance — no geriatric-specific data for bromazolam[20]model confidence 80%
Abstract confirms CYP3A4 as the dominant Phase I enzyme, directly supporting the hepatic impairment and CYP3A4 inhibitor contraindications. The remaining contraindications are class-level inferences standard in benzodiazepine pharmacology, consistent with this paper's role as the primary metabolism reference.
CYP3A4 involved in all phase I metabolism; UGT1A4 and UGT2B10 catalyze N-glucuronidation.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedRelative contraindications: * Hepatic impairment: CYP3A4-dependent metabolism predicts impaired clearance and prolonged exposure * History of substance use disorder: Full benzodiazepine agonist activity and documented reinforcing properties indicate high abuse liability * Concurrent use of CYP3A4 inhibitors: Predicted elevation of plasma concentrations * Pregnancy: Benzodiazepine-class teratogenicity risk; no bromazolam-specific reproductive toxicity data exist * Myasthenia gravis: GABA-A-mediated muscle relaxation may worsen neuromuscular junction impairment * Acute narrow-angle glaucoma: Standard benzodiazepine class contraindication * Elderly patients: Increased sensitivity to CNS depressants, fall risk, and likely reduced metabolic clearance — no geriatric-specific data for bromazolam[20]model confidence 80%
Duplicate of Pair 54. Abstract confirms CYP3A4 dominance in Phase I metabolism, directly supporting the CYP3A4-based contraindications. Other contraindications are class-level standard inferences.
CYP3A4 involved in all phase I metabolism; UGT1A4 and UGT2B10 catalyze N-glucuronidation.
checked by claude-sonnet-4-6 · May 8, 2026
comparative pharmacology7 claims6verified1inconclusive
verifiedBromazolam Ki values; alprazolam and diazepam Ki values are approximate published ranges from multiple sources[5]model confidence 92%
Abstract explicitly confirms bromazolam Ki values at α1 (2.8 nM), α2 (0.69 nM), and α5 (0.62 nM) subunits. This paper is cited specifically as the source for bromazolam Ki values.
Contains binding affinity (Ki) data for bromazolam at alpha1 (2.8 nM), alpha2 (0.69 nM), and alpha5 (0.62 nM) subunits.
checked by claude-sonnet-4-6 · May 8, 2026
inconclusiveThe additional involvement of CYP2B6 and CYP2C19 in bromazolam metabolism may introduce greater inter-individual pharmacokinetic variability than observed with alprazolam, though this comparison has not been directly studied.[20]model confidence 60%
Abstract states 'CYP3A4 involved in all phase I metabolism' but does not mention CYP2B6 or CYP2C19 involvement. The claim about these additional isoforms cannot be verified from the abstract alone.
CYP3A4 involved in all phase I metabolism.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHikin et al., Mérette et al., Green et al., Ballotari et al.[25]model confidence 88%
Citation [3] is the England and Wales 96-case coronial series (Hikin et al. based on scope). This citation is appropriately listed as one of the postmortem case series being referenced in the comparative summary.
96 coronial cases with bromazolam quantitation.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHikin et al., Mérette et al., Green et al., Ballotari et al.[13]model confidence 88%
Citation [6] is the British Columbia postmortem series (Mérette et al. based on scope). This citation is appropriately listed as one of the postmortem case series in the comparative summary.
First Canadian bromazolam postmortem report. First detected in BC January 2021.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHikin et al., Mérette et al., Green et al., Ballotari et al.[14]model confidence 88%
Citation [7] is the Jefferson County, AL case series (Green et al. based on scope). This citation is appropriately listed as one of the postmortem case series in the comparative summary.
10 postmortem cases with bromazolam May 2022–December 2023.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedHikin et al., Mérette et al., Green et al., Ballotari et al.[26]model confidence 88%
Citation [25] is the Florida GC-MS postmortem series (Ballotari et al. based on scope). This citation is appropriately listed as one of the postmortem case series in the comparative summary.
GC-MS method for designer BZDs in postmortem blood. 20 of 21 positive cases were bromazolam-positive.
checked by claude-sonnet-4-6 · May 8, 2026
verifiedIn most cases, multiple co-intoxicants were present, and bromazolam has not been confirmed as the sole cause of death in any published case.[25]model confidence 95%
Abstract explicitly states 'Bromazolam not associated with death in isolation from toxic concentrations,' directly confirming it has not been established as sole cause of death. Co-detections of cocaine, gabapentinoids, diazepam, and other designer BZDs confirm multiple co-intoxicants.
Bromazolam not associated with death in isolation from toxic concentrations. Cocaine, gabapentinoids, and diazepam most common co-detections.
checked by claude-sonnet-4-6 · May 8, 2026
Coverage & Gaps
Research Trail
substance-article pipeline-v5 May 8, 2026
| Step | Source | Query | Results |
|---|---|---|---|
| 1database lookup | PubChem | bromazolam | 1 result, 1 selected |
selection rationaleselection rationalePrimary chemical identity verification | |||
| 2literature search | PubMed | bromazolam benzodiazepine pharmacology | 13 results, 8 selected |
selection rationaleselection rationaleAll directly relevant to bromazolam pharmacology, toxicology, clinical presentation | |||
| 3literature search | OpenAlex | bromazolam novel benzodiazepine | 10 results, 5 selected |
selection rationaleselection rationaleLandmark reviews provide class-level context; specific bromazolam papers provide direct evidence | |||
| 4literature search | PubMed | bromazolam toxicology overdose death postmortem | 2 results, 1 selected |
selection rationaleselection rationaleJefferson County case series directly relevant to bromazolam concentrations in fatal overdose | |||
| 5clinical trial search | ClinicalTrials.gov | bromazolam | 0 results, 0 selected |
selection rationaleselection rationaleNo clinical trials exist - bromazolam has no approved medical use or investigational status | |||
| 6document retrieval | WHO ECDD | bromazolam WHO ECDD 45th meeting 2022 critical review | 1 result, 1 selected |
selection rationaleselection rationaleAuthoritative WHO regulatory review; contains binding affinity data from Clayton 2015, synthesis history, dosing, metabolism, legal status | |||
| 7legal status search | WebSearch | bromazolam legal status scheduling DEA US UK EU Canada Australia 2023 2024 2025 | 10 results, 4 selected |
selection rationaleselection rationalePrimary legal status documentation for key jurisdictions | |||
| 8literature search | PubMed | Clayton Poe Rallapalli pharmacophore alpha 5 GABA benzodiazepine receptor model | 1 result, 1 selected |
selection rationaleselection rationalePrimary source for GABA-A binding affinity data for bromazolam | |||
| 9literature search | PubMed | McDermott phenibut bromazolam use disorder withdrawal hospitalization | 1 result, 1 selected |
selection rationaleselection rationalePrimary published case report of bromazolam dependence/withdrawal | |||
| 10literature search | PubMed | Hester von Voigtlander aryl triazolo benzodiazepine pharmacological activity 1979 | 1 result, 1 selected |
selection rationaleselection rationaleOriginal synthesis paper documenting first preparation in 1970s | |||
| 11document retrieval | WHO ECDD 46th Meeting | bromazolam WHO ECDD 46th meeting 2023 updated critical review | 1 result, 1 selected |
selection rationaleselection rationaleUpdated WHO regulatory review with new in vitro binding data, animal pharmacology, and expanded epidemiology | |||
| 12data extraction | WHO ECDD 45th and 46th Meeting Reports | Extract all bromazolam pharmacology, dosing, metabolism, legal status data | 2 results, 3 selected |
selection rationaleselection rationalePrimary authoritative source for all bromazolam-specific data | |||
| 13legal status search | WebSearch | bromazolam UK Psychoactive Substances Act scheduling status 2024 2025 | 10 results, 2 selected |
selection rationaleselection rationaleLegal status verification for key jurisdictions | |||
| 14document retrieval | PubMed | McDermott phenibut bromazolam withdrawal case report | 1 result, 1 selected |
selection rationaleselection rationalePrimary source for dependence case evidence | |||
Research document (raw, unedited pipeline output)
# Research Output: Bromazolam --- ## Chemical Identity **PubChem CID:** 12562546 [Ref 1 — verified via PubChem API] **IUPAC name:** 8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine [Ref 17, Ref 21] **CAS registry number:** 71368-80-4 [Ref 17] **Molecular formula:** C₁₇H₁₃BrN₄ [Ref 17, Ref 21] *(verified against PubChem)* **Molecular weight:** 353.22 g/mol [Ref 17, Ref 21] *(verified against PubChem)* **InChIKey:** KCEIOBKDDQAYCM-UHFFFAOYSA-N [Ref 21] **Canonical SMILES:** BrC=1C=CC2=C(C1)C(=NCC3=NN=C(N32)C)C=4C=CC=CC4 [Ref 21] **InChI:** InChI=1S/C17H13BrN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3 [Ref 21] **International Nonproprietary Name (INN):** Not assigned [Ref 17, Ref 21] **Alternative chemical names:** - 8-Bromo-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine - 8-Bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine - DE(chloro)-bromo-alprazolam - XLI-268 (research designation) [Ref 17, Ref 21] **Physical form:** White crystalline solid [Ref 17]. On the illicit market, found in orange or green tablets and as yellow powder [Ref 21]. **Melting point:** 272.0–275 °C [Ref 17, Ref 21] **Solubility:** - Dimethylformamide: 30 mg/mL - Dimethylsulfoxide: 20 mg/mL - Ethanol: 10 mg/mL - Methanol: 1 mg/mL - DMF:PBS (pH 7.2, 1:1): 0.5 mg/mL [Ref 17, Ref 21] **Boiling point:** No published data [Ref 17, Ref 21] **Stereoisomers:** None described [Ref 17, Ref 21] **Structural relationship:** Bromazolam is a triazolobenzodiazepine structurally related to the internationally controlled substance alprazolam, in which the chlorine atom at position 8 is replaced by bromine. It is also structurally related to flubromazolam (from which it differs by lacking the fluorine at the C2 position of the phenyl ring) and to pyrazolam (in which the pyridinyl group has been replaced by a phenyl group) [Ref 17, Ref 21]. **Discrepancies with seed data:** The brief contained no SMILES, formula, weight, InChIKey, or PubChem CID. All have now been confirmed via PubChem (CID 12562546) and WHO ECDD reports. No contradictions found. --- ## Pharmacology ### Mechanism of Action Bromazolam is a positive allosteric modulator (PAM) of the γ-aminobutyric acid type A (GABA-A) receptor, acting at the classical benzodiazepine binding site within the GABA-A/benzodiazepine receptor complex. This mechanism is consistent with the broader benzodiazepine class [Ref 17, Ref 21]. ### Receptor Binding Affinity (Ki values) The only published study of bromazolam's binding affinity at GABA-A α subunit–containing receptors (Clayton et al. 2015 [Ref 14]) measured affinity in HEK cell membranes expressing recombinant GABA-A/benzodiazepine receptor subtypes (α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2, and α6β3γ2): | Receptor subtype | Ki (nM) | |---|---| | α1β3γ2 | 2.8 | | α2β3γ2 | 0.69 | | α5β3γ2 | 0.62 | | α3β3γ2 | No measurable binding | | α4β3γ2 | No measurable binding | | α6β3γ2 | No measurable binding | Bromazolam is non-selective for α subunits and shows relatively high affinity particularly at α2 and α5 subunits. No binding was detected at α3, α4, or α6 subunits [Ref 14, Ref 17, Ref 21]. **[FLAG — Safety-critical pharmacology:** The above Ki values come from a single published source (Clayton et al. 2015 [Ref 14]), a review paper in which bromazolam binding data appear as one entry among many compounds. This paper's primary focus was on the α5 pharmacophore model, not bromazolam characterization. The measurements were conducted by Cook JM's group at the University of Wisconsin. These Ki values are widely cited (WHO ECDD 45th and 46th reports both reference them) but have not been independently replicated in peer-reviewed literature.] ### Functional Activity (GABA-A) An unpublished report by Janowsky (Oregon Health and Science University, 2022, cited in WHO ECDD 46th Meeting [Ref 21]) assessed functional activity using: - **[³H]flunitrazepam displacement binding assay** at GABA-A (α1β3γ2) receptors in HEK cells: - Ki = 54 (± 17) nM **when GABA was present** - Ki = 1,750 (± 440) nM **when GABA was absent** - **Functional efficacy (electrophysiology):** EC₅₀ = 7.62 ± 0.82 nM; Emax = 88.0 ± 9.7% - Diazepam produced similar results in binding and functional assays [Ref 21] These results are consistent with full benzodiazepine agonism (high Emax ~88%) at GABA-A receptors. ### Abuse Potential — Animal Studies Paronis CA (McLean Hospital, 2022, cited in WHO ECDD 46th Meeting [Ref 21]) conducted a standard two-lever drug discrimination study in male rats trained to discriminate midazolam (0.3 mg/kg) from vehicle. Bromazolam (0.1–3 mg/kg): - Produced **full dose-dependent substitution** for midazolam - **ED₅₀ = 0.54 mg/kg** (95% CI: 0.26–1.12) - For comparison: midazolam ED₅₀ = 0.09 mg/kg; diazepam ED₅₀ = 0.66 mg/kg - Bromazolam did not affect response rates at tested doses - Midazolam-like effects at 3 mg/kg were **significantly attenuated by flumazenil (1 mg/kg)**, confirming on-target GABA-A/benzodiazepine receptor mediation - Morphine (negative control) did not substitute for midazolam [Ref 21] Interpretation: Bromazolam has similar potency to diazepam and approximately 6× less potency than midazolam in this procedure, consistent with classical benzodiazepine pharmacology. ### Pharmacokinetics **Routes of administration:** Oral (tablets, capsules, powder in solution, gummies) is the dominant route per law enforcement seizures and user reports [Ref 17, Ref 21]. Intravenous use was inferred from a syringe with bromazolam-containing solution found next to one fatality but is considered uncommon [Ref 17, Ref 21]. **Plasma concentrations:** In the only available human PK study, plasma bromazolam concentrations were determined from two clinical cases to be 6 µg/L and 29 µg/L respectively (Wagmann et al. 2021 [Ref 1]). These low concentrations underscore the need for sensitive analytical methods. **Metabolism:** Wagmann et al. (2021 [Ref 1]) characterized bromazolam metabolism using pooled human liver S9 fractions and confirmed with authentic human blood and urine samples. Eight metabolites were identified: *Phase I (hydroxylation):* - 4-hydroxy bromazolam (monohydroxylated) - α-hydroxy bromazolam (monohydroxylated) ← key metabolite - α-4-dihydroxy bromazolam (dehydroxylated) *Phase II (glucuronidation):* - α-hydroxy bromazolam glucuronide ← most abundant, recommended urine screening target - Bromazolam N-glucuronide ← most abundant, recommended urine screening target - Additional hydroxylated glucuronides **CYP enzyme involvement:** - Phase I: CYP2B6, CYP2C19, CYP3A4, CYP3A5, CYP2C9 - Phase II: UGT1A4, UGT2B10 (N-glucuronidation); multiple UGT isoforms for hydroxylated glucuronides [Ref 1, Ref 17, Ref 21] **Recommended urine screening targets:** - With conjugate cleavage: α-hydroxy glucuronide + N-glucuronide - Without conjugate cleavage: parent compound + α-hydroxy metabolite [Ref 1] **[GAP — Half-life/formal PK parameters:** No peer-reviewed pharmacokinetic study characterizing Tmax, Cmax, t½, volume of distribution, or oral bioavailability has been published. Community-reported estimates of ~16–20 hours half-life exist (unverified). Duration-of-action data (5–8 hours) comes from user-reporting sites and is anecdotal. This is a major gap for dose/duration data points.] --- ## History **First synthesis:** Bromazolam was first synthesized in the **1970s** by Hester JB Jr and von Voigtlander P, as part of a series of 1-substituted 6-aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines synthesized for potential CNS activity (Hester and Von Voigtlander 1979 [Ref 16]). The compound was originally developed as a candidate medication but was **never approved for clinical use** [Ref 17, Ref 21]. **Synthesis route:** The 1,4-benzodiazepine precursor is prepared by cyclization of 2-amino-5-bromobenzophenone with chloroacetylchloride, followed by ammonia treatment to promote ring closure via imine formation. A triazole ring is then introduced via reaction with hydroxyacetic acid hydrazide. This synthesis requires chemical laboratory equipment and qualified personnel [Ref 17, Ref 21]. **Market emergence:** - First documented government detection: **Sweden, 2016** [Ref 17, Ref 21] - First US reports: **2019** [Ref 17, Ref 21] - First detected in British Columbia, Canada: **January 2021** (Mérette et al. 2023 [Ref 6]) - First detected in Jefferson County, Alabama: **May 2022** (Green et al. 2024 [Ref 7]) - By 46th ECDD meeting (October 2023): detected in **17 countries** — Australia, Austria, Canada, China, Estonia, Finland, Germany, Iceland, Luxembourg, India, Netherlands, New Zealand, Russian Federation, Sweden, Switzerland, UK (Wales), USA [Ref 21] - IONICS reported 118 seizures between 2020 and August 2023 [Ref 21] **Regulatory milestones:** - WHO ECDD 45th meeting (October 2022): Bromazolam critically reviewed; recommended for continued surveillance [Ref 17] - WHO ECDD 46th meeting (October 2023): Critically reviewed again; international control not yet in place [Ref 21] - UN Convention on Psychotropic Substances: bromazolam added to Schedule IV (March 2024) following WHO recommendation [Ref 20] - UK: Class C under Misuse of Drugs Act 1971 (March 2024) [Ref 19] - US: DEA emergency Schedule I placement, published December 15, 2025; effective March 18, 2026 [Ref 18] **Appearance in novel food products:** Bromazolam was detected in two of 65 chocolate samples submitted to the National Anti-Drug Laboratory of China for NPS analysis (Song et al. 2023), raising concerns about unintentional exposure including pediatric cases [Ref 21]. --- ## Subjective Effects The primary source of information about bromazolam's psychological effects is **anecdotal self-reports on online forums** (Bluelight, Reddit). No controlled human studies have characterized subjective effects. The WHO ECDD reports note that all online forum posts should be considered anecdotal, as no analytical confirmation of sole bromazolam use was obtained [Ref 17, Ref 21]. **Self-reported effects from user forum data (all anecdotal, uncontrolled):** - Hypnotic and sedative effects [Ref 17, Ref 21] - Muscle relaxation [Ref 17, Ref 21] - Analgesia/pain relief [Ref 17, Ref 21] - Euphoria [Ref 17, Ref 21] - Increased confidence [Ref 17, Ref 21] - Empathy enhancement [Ref 17, Ref 21] - Amnesia — reported by some users; others note it is **less pronounced than with other benzodiazepines** [Ref 17, Ref 21] - "Delusions of sobriety" — specifically noted in community reports, described as a particular feature of bromazolam vs. other RC benzodiazepines [Ref 17] **Use motivations** (from user forums): - Intentional recreation (anxiolytic/hypnotic effects) - Self-medication for anxiety - Sleep induction - "Coming down" from stimulants (methamphetamine) [Ref 17, Ref 21] **Doses (community-reported, from informational website TripSit; anecdotal):** | Level | Dose | |---|---| | Light | 0.5–1 mg | | Common | 1–2 mg | | Strong | 2–≥4 mg | **For comparison, diazepam doses from same source:** light 2.5–5 mg; common 5–15 mg; heavy 15–30 mg. A review of NPS benzodiazepines cited 1 mg as a "typical recreational dose" [Ref 11, Ref 17, Ref 21]. This dose comparison suggests bromazolam is approximately 5–10× more potent than diazepam on a mg-per-mg basis (structural analog inference; no controlled human comparison). **Onset/duration (community-reported, anecdotal):** - Onset: 15–45 min after oral administration - Duration of action: 5–8 hours - After-effects: 1–12 hours [Ref 17, Ref 21] **[FLAG — Dose/duration data:** All dosing and duration information is anecdotal, sourced from user-reporting websites. No controlled human pharmacokinetic studies have been conducted. The WHO ECDD specifically notes "caution is suggested in interpreting these data" [Ref 17]. Duration may be influenced by inter-individual CYP variability and polydrug use context.] --- ## Safety & Toxicity ### Preclinical Toxicology No studies of the preclinical toxicology of bromazolam are available. No LD₅₀ data exist [Ref 17, Ref 21]. **[FLAG — Safety-critical gap:** No LD₅₀, therapeutic index, or organ toxicity data have been published. Toxicity projections rely entirely on class-level (benzodiazepine) inference.] ### Clinical Case Reports and Adverse Events **Germany:** Two patients with confirmed bromazolam use were found unconscious or minimally responsive (Wagmann et al. 2021 [Ref 1]; WHO ECDD 45th, 46th meetings [Ref 17, Ref 21]). **Chicago, February 2023 (MMWR):** Ehlers et al. (2024 [Ref 5]) reported a cluster of three young adults who consumed bromazolam disguised as counterfeit alprazolam. They presented with **seizures, hyperthermia, and myocardial injury** — an atypical presentation exceeding typical benzodiazepine toxicity. The authors noted that high-dose bromazolam may produce severe toxicity inconsistent with standard benzodiazepine class expectations. This is the only published report of bromazolam-associated seizures, hyperthermia, and cardiac injury. **Farah et al. (2026 [Ref 27]):** Case series of 32 patients presenting with bromazolam-positive urines at a US emergency department; detailed clinical data not yet available in the abstract. **Falise et al. (2025 [Ref 9]):** US ED patients with confirmed bromazolam exposure presenting for opioid/stimulant non-fatal overdose. Documents bromazolam as an adulterant in the illicit drug supply. **Cembellin-Kao et al. (2025 [Ref 10]):** Occult (unknown) bromazolam exposure in patients presenting for other overdoses; documents bromazolam as an adulterant in North American drug supply. **Dunlop et al. (2025 ASSIST study [Ref 2]):** Clinical characterization of analytically confirmed bromazolam use in Scotland; bromazolam is the predominant novel benzodiazepine in "street valium" in Scotland. In 2023, 58% of Scottish drug-related deaths involved benzodiazepines. ### Postmortem Blood Concentrations | Study | Setting | n cases | Mean concentration | Range | |---|---|---|---|---| | Hikin et al. 2024 [Ref 3] | England/Wales | 96 | 64.6 µg/L (64.6 ng/mL) | <1–425 µg/L | | Mérette et al. 2023 [Ref 6] | British Columbia | 41 | 11.4 ng/mL | 0.5–319.3 ng/mL | | Green et al. 2024 [Ref 7] | Jefferson County, AL | 10 | 401 ng/mL | 21–3220 ng/mL | | Ballotari et al. 2025 [Ref 25] | Florida | 20 | 59.1 ng/mL | 5.9–352 ng/mL | The concentration ranges vary considerably across studies, likely reflecting differences in analytical methods, case selection, and specimen timing. **Bromazolam has not been associated with death in isolation from resulting toxic concentrations; in most cases, multiple co-intoxicants were present.** [Ref 3] ### Fentanyl Co-Detection - US (2022): 75% of bromazolam-positive samples also contained fentanyl [Ref 17] - Canada (2020–2021): fentanyl in 88% of 41 postmortem bromazolam-positive cases [Ref 21] - England/Wales (2021–2022): cocaine, gabapentinoids, and diazepam most common co-detections; 48% had at least one other designer BZD [Ref 3] Synergistic CNS and respiratory depression from the BZD-opioid combination is the dominant mechanism in most fatal cases (Hughes et al. 2026 [Ref 26]). ### San Francisco Fatalities (Rodda 2024) 44 bromazolam-related fatalities in San Francisco in 2023 alone — a marked surge compared to previous years. Demographics: predominantly male; significant proportion without fixed addresses. Blood concentrations increased during the study period, suggesting increased availability and/or purity (Rodda 2024 [Ref 4]). ### Impaired Driving Bromazolam has been detected in biological samples from impaired drivers in the USA; average blood concentration 61 ng/mL (± 47 SD) [Ref 17]. --- ## Harm Reduction ### Key Identified Risks 1. **Adulterant risk:** Bromazolam is frequently sold in counterfeit alprazolam/Xanax or diazepam/Valium tablets, or found as an adulterant in opioid and stimulant supplies [Ref 5, Ref 9, Ref 10]. Users may consume bromazolam unknowingly. 2. **Opioid combination:** Synergistic respiratory depression with fentanyl and other opioids is the most common mechanism in fatal cases [Ref 26, Ref 4]. Naloxone may partially reverse opioid components but does not reverse benzodiazepine effects. 3. **Dosing inconsistency:** Illicit tablets and infused paper/cards show extreme dose variability (0.34–2.33 mg/tablet in Scottish prison samples) (Marland et al. 2024 [Ref 24]). 4. **Withdrawal risk:** Abrupt cessation after chronic use can produce life-threatening seizures [Ref 8]. Established diazepam equivalency dosing for bromazolam withdrawal is not yet published. 5. **Delusions of sobriety:** Users specifically report that bromazolam produces prominent "delusions of sobriety," making it difficult to self-assess impairment — potentially leading to dangerous re-dosing or driving [Ref 17]. 6. **Testing:** Standard immunoassay benzodiazepine screens may not detect bromazolam reliably; LC-MS/MS or HRMS required for analytical confirmation (Wagmann et al. 2021 [Ref 1]). ### Drug Testing Fentanyl test strips and standard drug checking services may help identify presence of opioid adulterants. Bromazolam cannot be identified by standard urine immunoassay benzodiazepine kits reliably; specialized LC-MS/MS panels are required [Ref 1]. ### Flumazenil Flumazenil (benzodiazepine antagonist) reversal of bromazolam effects was confirmed in the rat drug discrimination model at 1 mg/kg [Ref 21]. Clinical use in humans would follow standard protocols for benzodiazepine overdose, though caution is warranted in polydrug contexts. --- ## Tolerance & Dependence ### Tolerance No formal tolerance studies exist for bromazolam specifically. By class inference, GABA-A receptor downregulation and subunit composition changes are expected with chronic use (consistent with all benzodiazepines) [Ref 12 — Navarrete et al. 2026 review]. ### Dependence No formal dependence studies have been conducted [Ref 17, Ref 21]. **Published case evidence:** **McDermott et al. (2022 [Ref 15]):** First published case report of bromazolam and phenibut use disorders requiring hospitalization for medically supervised withdrawal. Documents that established BZD equivalency dosing for bromazolam was not available, complicating clinical management. **Butler et al. (2025 [Ref 8]):** Case report of a male in his early 20s who presented with a **seizure** following abrupt cessation of multiple illicit substances including bromazolam, flubromazepam, alcohol, kratom, tianeptine, and phenibut. No approved long-acting BZD equivalents for bromazolam were available. Kratom's inhibition of BZD metabolism (via CYP inhibition) was noted as a complicating factor. Symptom-based diazepam stabilization was used [Ref 8]. **Anecdotal reports (online forums, cited in WHO ECDD):** Multiple users have reported difficulty withdrawing from bromazolam after chronic use. At least one case of withdrawal-associated psychosis and hallucinations was reported after repeated bromazolam use in combination with phenibut [Ref 17, Ref 21]. ### Cross-Tolerance By class inference, bromazolam would be expected to show full cross-tolerance with other GABA-A positive allosteric modulators (benzodiazepines, alcohol, barbiturates, Z-drugs). No substance-specific studies. **[FLAG — Dose equivalency gap:** No published bromazolam-to-diazepam equivalency has been established. This is clinically significant for withdrawal management. The Butler 2025 [Ref 8] and McDermott 2022 [Ref 15] case reports both highlight this gap.] --- ## Interactions **Opioids (HIGH SEVERITY):** Synergistic CNS and respiratory depression, significantly potentiated at all dose levels. Co-detection with fentanyl in 75–88% of postmortem samples [Ref 17, Ref 21]. Naloxone reverses opioid but not benzodiazepine component [Ref 26]. **Ethanol:** Additive-to-synergistic CNS/respiratory depression by class [Ref 12]. No bromazolam-specific human studies. **Other CNS depressants (gabapentinoids, barbiturates, z-drugs, other BZDs):** Additive CNS depression; gabapentinoids (pregabalin, gabapentin) frequently co-detected in UK coronial cases with bromazolam [Ref 3]. **Stimulants (methamphetamine, cocaine):** Frequently co-detected in fatalities; used intentionally to "come down" from stimulant effects. Co-presence of CNS stimulants does not protect against respiratory depression and may mask perceived sedation level [Ref 9, Ref 25]. **CYP3A4 inhibitors** (azole antifungals, macrolide antibiotics, grapefruit juice): Expected to increase bromazolam plasma concentrations and effect duration; CYP3A4 is the dominant phase I pathway [Ref 1]. **CYP3A4 inducers** (rifampin, carbamazepine, St. John's wort): Expected to decrease bromazolam plasma levels [Ref 1]. **Kratom:** Kratom (mitragynine) inhibits CYP enzymes including those involved in BZD metabolism, potentially prolonging bromazolam exposure [Ref 8]. **Phenibut:** Co-dependence documented (McDermott 2022 [Ref 15]); both GABA-ergic; combined withdrawal associated with psychosis [Ref 17]. --- ## Legal Status | Jurisdiction | Status | Details | Date | |---|---|---|---| | **International (UN)** | Schedule IV, Convention on Psychotropic Substances | Added following WHO ECDD 46th meeting recommendation | March 2024 [Ref 20] | | **United States** | Schedule I (temporary emergency) | DEA emergency placement; Federal Register 2025-22763 | Effective March 18, 2026 [Ref 18] | | **United Kingdom** | Class C, Misuse of Drugs Act 1971 | SI 2024/248 (England, Wales & Scotland) | 2024 [Ref 19] | | **Canada** | Schedule IV, Controlled Drugs and Substances Act | Pre-2022 | [Ref 17] | | **Germany** | Controlled under NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Psychoactive drug regulations | [Ref 17] | | **Finland** | Listed for formal surveillance; subsequently scheduled under Narcotics Act | Finnish Medicines Agency, Feb 14, 2022 | [Ref 21] | | **Australia** | Detected; subject to import controls; scheduling under Poisons Standard unclear | Victoria Department of Health alert issued 2022 | [Ref 21] | | **EU member states** | Subject to EU Council Decision 2024/832 implementing UN Schedule IV | Post-March 2024 | [Ref 20] | **Note on US status prior to March 2026:** Before federal temporary scheduling, bromazolam was not explicitly scheduled under the Controlled Substances Act at the federal level. Several US states had enacted state-level controls. The Federal Analog Act could potentially apply (structural analog of alprazolam, a Schedule IV substance) but application varies by jurisdiction. **[FLAG — Legal status:** Australia's specific Poisons Standard scheduling status for bromazolam was not definitively confirmed via primary source. The 2022 Victoria Department of Health alert was issued, and bromazolam has been detected in Australian postmortem cases [Ref 23, Ref 22], but the current TGA Poisons Standard entry could not be verified.] --- ## Clinical Trials **No clinical trials found.** A search of ClinicalTrials.gov returned zero registered studies for bromazolam. Bromazolam has no marketing authorization, no approved therapeutic use, and no investigational new drug (IND) status in any jurisdiction [Ref 17, Ref 21]. --- ## Community Feedback Analysis No community feedback was submitted in the brief's Part A2 section. --- ## Gaps & Flags ### Critical Safety Flags (require editorial review before publication) 1. **[FLAG] No LD₅₀ or preclinical toxicity data:** No animal toxicity studies, no therapeutic index, no dose-lethality data exist for bromazolam. Any dose range published must be flagged as anecdotal. 2. **[FLAG] No validated half-life:** No peer-reviewed PK study has determined t½. Duration-of-action claims (5–8 h) and residual effect claims (1–12 h) are from user-reporting sites and are anecdotal. A web source cited 31 hours as an estimate but the primary source could not be verified. 3. **[FLAG] No diazepam equivalency established:** Clinical case reports explicitly note the absence of a validated BZD equivalency dose for bromazolam withdrawal, complicating harm reduction and clinical management guidance. 4. **[FLAG] Ki values from single unspecialized source:** The only published binding affinity data (Clayton et al. 2015 [Ref 14]) measured bromazolam Ki as an incidental finding in a pharmacophore review paper. These values have not been independently confirmed. 5. **[FLAG] Janowsky 2022 functional data unpublished:** The EC50 and Emax values (from WHO ECDD 46th report [Ref 21]) come from an unpublished internal report from Oregon Health and Science University. Not peer-reviewed. 6. **[FLAG] Chicago MMWR cluster (seizures, hyperthermia, myocardial injury [Ref 5]):** This atypical presentation — potentially reflecting very high-dose exposure or bromazolam-specific off-target effects — warrants prominent safety notice. Standard benzodiazepine toxicity does not typically produce seizures (except during withdrawal) or hyperthermia. 7. **[FLAG] Australia scheduling unconfirmed:** Specific Poisons Standard entry for bromazolam in Australia could not be verified from primary sources. ### Data Gaps for Article Content - **No controlled human studies** characterizing subjective effects, dose-response, onset, or duration - **No plasma half-life** formally determined in humans - **No bioavailability data** for any route of administration - **No protein binding data** for bromazolam - **No CNS penetration/volume of distribution data** - **No organ-specific toxicity studies** (hepatotoxicity, nephrotoxicity, cardiotoxicity) - **No data on tolerance development rate** specific to bromazolam - **No published diazepam-equivalent dose conversion** - **No data on pediatric or geriatric pharmacokinetics** - **Animal discrimination data** (Paronis 2022, McLean Hospital) cited in WHO ECDD 46th report but unpublished in peer-reviewed literature ### Structural Analog Inference Used Where bromazolam-specific data are absent, class-level inference from benzodiazepines (particularly alprazolam, as the chloro analogue) has been applied for the following claims: - Cross-tolerance with other GABAergic depressants - Alcohol interaction severity - Tolerance development mechanism - Withdrawal seizure risk after chronic use - Pharmacological effects of CYP3A4 interactions These inferences should be clearly labeled as class-level in article prose.